research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
Search
for
Sort by
Research
180-210 / 1000+ resultsresearch Pharmacological evidence for the involvement of adenosine triphosphate sensitive potassium channels in chloroquine-induced itch in mice
ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.
research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future
Hair regrowth improved, but quality of life did not.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Quality of Life Assessment in Male Patients With Androgenetic Alopecia
Androgenetic alopecia affects men's emotions more than symptoms or daily function.
research Impact on Quality of Life in Patients with Alopecia Areata and Androgenetic Alopecia: A Cross-Sectional Observational Study at A Tertiary Care Centre in Eastern Bihar
Hair loss significantly affects emotional and social well-being.
research Uncontrolled Clinical Trial of Quality- and Quantity-cultured Peripheral Blood Mononuclear Cell Treatment for Androgenic Alopecia
MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.
research Impact on Quality of Life in Patients with Alopecia Areata and Androgenetic Alopecia: A Cross-Sectional Observational Study at A Tertiary Care Centre in Eastern Bihar
Hair loss significantly affects emotional and social well-being.
research Quality-of-Life Assessment in Singaporean Children with Alopecia Areata
Children with alopecia areata in Singapore generally have a good quality of life.
research Qualidade de vida relacionada à saúde em homens e mulheres com alopecia androgenética em uso de terapia com luz de baixa intensidade
Low-Level Light Therapy improves quality of life more for women than men with hair loss.
research Association between air quality index and risk of alopecia areata: A nationwide population-based cohort study
Higher air pollution increases the risk of alopecia areata.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research QbD-Enabled Development of Quercetin Dihydrate-Loaded Nanostructured Lipid Carriers: In vitro Characterization, Safety and Efficacy Assessment in Androgenetic Alopecia Mice Model
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Telogen effluvium. New possibilities of correction
Combining iron supplements with Qilib lotion is more effective for treating hair loss from iron deficiency.
research Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
research Isoallopregnanolone reduces tic‐like behaviours in the D1 CT ‐7 mouse model of Tourette syndrome
Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Androgenetic Alopecia in Al-Qalyubia Governorate: A Comprehensive Review
Current treatments for androgenetic alopecia manage symptoms but don't cure it, and it affects social and psychological well-being.
research Monthly versus quarterly dutasteride mesotherapy for male androgenetic alopecia: A randomized trial
research Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
Disease-specific tools better assess quality of life in alopecia areata patients.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Result of a Prospective, Multicenter Study
Men with hair loss experience lower quality of life, worsened by factors like age, severity, and treatment history.
research Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
research Effectiveness of QR678 and QR678 Neo ® with intralesional corticosteroid vs. intralesional corticosteroid alone in the treatment of alopecia areata –A randomized, comparative, prospective study
QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Quality of life assessment in patients with androgenetic alopecia
Androgenetic alopecia significantly harms quality of life, affecting emotions and relationships.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.